LIVN News and Press, LivaNova PLC From 02/26/19

AES , AMRN , AMT , ANIP , BBY , CHK , CLH , CPB , DF , DNR , DOC , DY , EYE , FTDR , GCP , GTE , HMLP , HPT , HZNP , IONS , LIVN , LOW , LXP , MDCO , MGPI , MIDD , NEWM , NOVT , OCN , ODP , PEG , PGTI , PNM , RDC , SBGI , SHOO , TAST , TJX , UTHR F...

New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has add...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval ® sutureless aortic heart valve to treat aortic valve disease. By adding ...

Company plans to submit clinical study protocol for CMS consideration LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on Wednesday, Feb. 27, 2019 at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fou...

Strong Broad-Based Growth; Recent Discussion Focused on MitraClip Abbott Laboratories ( ABT ) is a diversified healthcare conglomerate with revenue coming from Medical Devices, Nutrition, Diagnostics, and Established Pharma (generic pharmaceuticals). The stock has performed well as its segme...

Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for sutureless aortic valve replacemen...

Analysis finds overall cost savings far exceed system-related costs LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that a new cost analysis found the Company’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System results in lowe...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/16/2018. Please visit our Tracking Soros Fund Management Holdings article for an ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System for patients with drug-resistant...